ACLX News and Press, Arcellx Inc. From 06/19/23

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program PR Newswire -- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif. , June 19, 2023 /PRNews...

2023-06-02 10:02:23 ET Gainers: Connect Biopharma ( CNTB ) +26% . LAVA Therapeutics ( LVTX ) +19% . Panbela Therapeutics ( PBLA ) +18% . Apollomics ( APLM ) +15% .  Rockwell Medical ( RMTI ) +10% . Losers: Kiora Pharm...

2023-05-08 17:05:24 ET Arcellx press release ( NASDAQ: ACLX ): Q1 GAAP EPS of -$0.58. Revenue of $17.91M. For further details see: Arcellx GAAP EPS of -$0.58, revenue of $17.91M

Arcellx Provides First Quarter Financial Results PR Newswire REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference PR Newswire REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development o...

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights PR Newswire -- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-te...

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference PR Newswire REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovativ...

H.C. Wainwright has initiated Arcellx ( NASDAQ: ACLX ) with a buy saying that the company's CAR-T therapies in development have advantages over marketed ones and its partnership with Gilead Sciences' ( GILD ) Kite Therapeutics will reap benefits. The firm has a $42 price target (~...

Arcellx to Participate in Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patien...